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ABSTRACT
The CXCR4 receptor (Chemokine C-X-C motif receptor 4) is highly expressed 
in different hematological malignancies including chronic lymphocytic leukemia 
(CLL). The CXCR4 ligand (CXCL12) stimulates CXCR4 promoting cell survival and 
proliferation, and may contribute to the tropism of leukemia cells towards lymphoid 
tissues. Therefore, strategies targeting CXCR4 may constitute an effective therapeutic 
approach for CLL. To address that question, we studied the effect of Ulocuplumab 
(BMS-936564), a fully human IgG4 anti-CXCR4 antibody, using a stroma – CLL cells 
co-culture model. We found that Ulocuplumab (BMS-936564) inhibited CXCL12 
mediated CXCR4 activation-migration of CLL cells at nanomolar concentrations. This 
effect was comparable to AMD3100 (Plerixafor - Mozobil), a small molecule CXCR4 
inhibitor. However, Ulocuplumab (BMS-936564) but not AMD3100 induced apoptosis 
in CLL at nanomolar concentrations in the presence or absence of stromal cell support. 
This pro-apoptotic effect was independent of CLL high-risk prognostic markers, was 
associated with production of reactive oxygen species and did not require caspase 
activation. Overall, these findings are evidence that Ulocuplumab (BMS-936564) has 
biological activity in CLL, highlight the relevance of the CXCR4-CXCL12 pathway as a 
therapeutic target in CLL, and provide biological rationale for ongoing clinical trials 
in CLL and other hematological malignancies.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the 
most frequent adult leukemia and is characterized by 
accumulation of aberrant B-lymphocytes [1]. Stromal 
cell support of CLL cells has shown survival through 
membrane-associated factors such as CXCR4 (chemokine 
C-X-C motif receptor 4). CXCR4 is a G protein coupled 
receptor consisting of 7 transmembrane domains, [2] 
that is expressed in different cell types, including B 
cells, monocytes, T cells, neutrophils, macrophages, 
natural killer (NK) cells, endothelial, epithelial, CD34+ 
hematopoietic stem cells, and dendritic cells [3-6]. 
CXCR4 not only is expressed in CLL but also in a variety 
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of cancers including acute myeloid leukemia, myeloma, 
lymphomas, clear cell renal cell carcinoma, breast, lung, 
colon, pancreatic, and ovarian cancer [7]. CXCR4 has a 
single ligand, CXCL12 (chemokine C-X-C motif ligand 
12), [8] which is a homeostatic chemokine also known as 
stromal cell-derived factor 1 (SDF-1). CXCL12 regulates 
hematopoietic cell trafficking, secondary lymphoid tissue 
architecture, and homing of hematopoietic stem cells 
(HSC) to the bone marrow [5]. In addition, CXCL12 
mediates survival, proliferation of B-cell progenitors and 
CLL cells, [9, 10] and participates in vitro in stromal cell 
dependent resistance to cytotoxic drugs like fludarabine 
(F-ara-A), [6] or steroids [11]. Therefore, CXCL12 
mediated activation of CXCR4 may favor resistance to 
therapy in CLL patients by promoting and maintaining 
minimal residual disease [12-14].
Several anti-CXCR4 antibodies are currently 
available including MAbs 6H7, 7D4, 1D9, and 12G5, 
[15-16] which are used primarily as reagents for flow 
cytometry or immunohistochemistry. Ulocuplumab 
(BMS-936564, Bristol-Myers Squibb) is a novel IgG4 
fully human monoclonal antibody that binds to the second 
extracellular loop of CXCR4. 
Ulocuplumab (BMS-936564) binds to CXCR4 
at low nanomolar concentrations compared to other 
commercially available antibodies (e.g. 1D9). This 
antibody prevents the binding of CXCL12 and inhibits 
calcium flux mediated cell motility and migration [17]. 
The Ulocuplumab (BMS-936564) antibody is an IgG4 
[17], that lacks complement-dependent cytotoxicity 
activity (CDC) and antibody-dependent cell-mediated 
cytotoxicity (ADCC) activity as confirmed in the current 
study in primary CLL and Ramos cell lines. Therefore, 
most of its anti-cancer activity is possibly mediated 
by direct binding to CXCR4 and interference with the 
interaction to its ligand (CXCL12). Here, we present our 
studies with primary leukemia cells from CLL patients 
using Ulocuplumab (BMS-936564) in culture conditions 
that resemble the leukemia microenvironment.
RESULTS
Expression of CXCR4 and CXCL12 in CLL, 
normal B, and stroma-NK-tert cells 
Expression of CXCR4 and CXCL12 was assessed 
by flow cytometry in primary leukemia cells from patients 
with CLL as well as in normal B, and stroma-NK-tert cells 
(Figure 1A and 1B). Additionally, established cell lines 
used in our experiments as controls were evaluated for 
CXCR4 expression (Figure 1 and Supplementary Figure 
1).
We observed that the level of expression of CXCR4 
was higher in CLL by at least 8 fold when compared to 
normal B cells. As expected, CXCL12 expression was not 
detected in CLL cells but was high in stroma-NK-tert cells 
(Figure 1B), and other leukemia and lymphoma cell lines 
(Figure 2A-2B and Supplementary Figure 2).
We evaluated a group of 20 patients categorized 
as CLL-HR and 20 patients categorized as CLL-LR 
(defined by using prognostic markers discussed above). 
We observed that the level of CXCR4 expression was 
independent of prognostic factors with an average ∆MFI 
(mean fluorescence intensity) of 432.2 (95% CI 314.5-
549.9) (Figure 1C). There was no significant difference 
between CLL-HR and CLL-LR subtypes of CLL, but there 
was a significant difference between CLL subtypes versus 
normal B cells (p < 0.0001) with a level of expression 
that was 8 fold lower compared with CLL samples (∆MFI 
average of 26.07 - 95% CI 11.6-40.5, p <0.01). 
Table 1: List of cell lines used in the study
Name of Cell Line Leukemia/Lymphoma Cell Type Media for Growth
MEC1 CLL Lymphoblast
RPMI with 10% FBS and 1% Pen-
Strep
K562 CML Lymphoblast
JVM2 MCL Lymphoblast
Raji BL Lymphoblast-like cells
Ramos BL B lymphocytes
Jurkat Acute T cell leukemia T lymphocyte
Granta BCL B cell lymphoma
EW36 BCL B cell lymphoma
Daudi BL B lymphoblast
Mino MCL Lymphoblast
Namalwa BCL B cell lymphoma
JeKo-1 MCL Lymphoblast
BL: Burkitt’s lymphoma, BCL: B cell lymphoma, CLL: chronic lymphocytic leukemia, CML: chronic myelogenous leukemia, 
MCC: mantle cell lymphoma, FBS: fetal bovine serum
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Affinity and saturation binding of 
125I-BMS-936564 to CXCR4
We determined affinity and saturation binding 
of Ulocuplumab (BMS-936564) to CXCR4 using a 
radiolabeled antibody 125I-BMS-936564 in Ramos cell line 
(Burkitt’s lymphoma). In comparison to K562 (chronic 
myelogenous leukemia, Figure 2A), there was high level 
of CXCR4 expression in Ramos cell line (Figure 2B). 
Competitive affinity binding of Ulocuplumab (BMS-
936564) showed a mean KD (the equilibrium dissociation) 
of 2.8 nM and approximately 150,000 CXCR4 receptors 
per cell in B-lymphoma cells (Ramos, Figure 2C). Specific 
binding affinity of this antibody to human PBMCs was 
lower - 5.9 nM (Figure 2D), and the number of receptors 
per cell that was approximately one third of that found in 
human PBMCs (61,000 per cell). 
Ulocuplumab (BMS-936564) (IgG4 antibody) 
lacks ADCC or CDC activity but induces 
apoptosis mediated by CXCR4 binding
Ulocuplumab (BMS-936564) was engineered as 
a fully human IgG4 antibody with the purpose to lack 
ADCC or CDC activity and to work as a “blocking 
antibody”. We tested this antibody in vitro to demonstrate 
the lack of those two important functions. 
Ramos and PBMC effector cells were incubated 
with increasing concentrations of Ulocuplumab (BMS-
936564) to evaluate antibody dependent cellular 
cytotoxicity (ADCC) (Figure 2E), or with complement 
(CDC) (Figure 2F). Ulocuplumab (BMS-936564) did 
not induce cytotoxicity in the CLL-B cells (target cells) 
mediated by effector cell mechanisms (ADCC, Figure 2G) 
or by complement (CDC, Figure 2H).
We analyzed whether direct binding of CXCR4 
could trigger apoptosis. K562 (CXCR4-, Figure 2A), 
and Ramos (CXCR4+, Figure 2B) were incubated with 
increasing concentrations of Ulocuplumab (BMS-936564) 
and then analyzed for development of apoptosis using flow 
cytometry. Only Ramos cells, which express high levels of 
CXCR4, underwent apoptosis (IC50 1.9 nM) while K562 
cells did not show evidence of cell death even when the 
antibody was used at high mM concentrations (Figure 
3A). Before screening the primary CLL cells, we carried 
out washout experiments using the equivalent in vivo 
achievable concentration of Ulocuplumab (BMS-936564) 
(67 nM or 10 ug/ml). We found that the cells started to 
show in vitro cytotoxic effect within 5-10 hrs of treatment. 
It seems that Ulocuplumab (BMS-936564) saturates the 
cells in terms of cell death as the changes in CLL or CLL 
co-cultured with stroma-NK-tert cells become steady 
(Supplementary Figure 3). Similar dose dependent pro-
apoptotic activity was observed in primary leukemia cells 
from CLL patients (IC50 of 12.43 nM). Interestingly, the 
activity of Ulocuplumab (BMS-936564) was present 
whether or not the leukemia cells were cultured alone 
or with stromal cell support. This indicates that the 
activity of Ulocuplumab (BMS-936564) is likely due to 
direct binding to CXCR4 rather than interference of the 
CXCR4-CXCL12 receptor / ligand interaction. Moreover, 
this antibody was able to overcome fludarabine resistance 
conferred by stromal cells in this in vitro model (Figure 
3B). AMD3100, which binds and inhibits signaling 
through CXCR4, was used as a control. Importantly, this 
molecule did not induce cell death in CLL or any of the 
cell lines tested (Figure 3B, and data not shown). 
Figure 1: CXCR4 and CXCL12 expression in CLL, normal B and stroma cells. A. Expression of CXCR4 after surface 
staining using an anti-CXCR4 antibody in B cells derived from CLL patients, healthy volunteers, and stroma-NK-tert cells, as compared to 
the respective isotype. B. Expression of CXCL12 after intracellular staining using an anti-CXCL12 antibody in B cells derived from CLL 
patients, and normal PBMCs from healthy volunteers, and stroma-NK-tert cells, as compared to the isotype. C. Panel shows the CXCR4 
expression in samples from CLL patients with high risk and low risk characteristics and normal B cells. The line indicates the mean of each 
group.
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Table 2: IC50 of Anti-CXCR4 antibodies (1D9, 12G5, and BMS-936564) in leukemia/lymphoma 
cell lines
Cell Lines CXCR4 (ΔMFI)
IC50 (nM)
BMS-936564 12G5 1D9
JVM2 0.65 NA NA NA
MEC1 0.8 NA NA NA
K562 1.2 NA NA NA
Granta 4.88 25.39 19.3 45.96
JeKo-1 22.75 1.86 49.41 584.47
EW36 27.76 0.00348 1550 990
Daudi 29.78 0.000955 9.81 874.67
Mino 56.71 628.93 2650 3010
Jurkat 71.06 15.49 626.93 270.27
Ramos 76.43 3.01 24.91 1980
Raji 82.72 8.85 245.93 32.99
Namalwa 181.2 2.57 28.52 597
NA: IC50 not achievable
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Figure 2: Scatchard analysis of Ulocuplumab (BMS-936564) binding to Ramos cells, human PBMCs and ADCC & 
CDC activity in Ramos cell line (Burkitt’s lymphoma). A. CXCR4 Expression profiling was done using an anti-CXCR4 antibody 
for surface staining in K562 and B. Ramos cell lines followed by analysis of samples using flow cytometry. The CXCR4 expression is 
presented in form of ∆MFI. C. The affinity of Ulocuplumab (BMS-936564) was measured using endogenously expressed CXCR4 positive 
Ramos cells. The binding capacity of 125I-Ulocuplumab (BMS-936564) to CXCR4+ cells in presence or absence of excess unlabeled 
antibody was determined and a Kd of 2.9 nM and approximately 1.5x10
5 receptors/cell was calculated. D. Normal peripheral blood cells 
were incubated with increasing concentrations of 125I-Ulocuplumab (BMS-936564). The counts per minute bound (CPM) in the presence 
or absence of unlabeled antibody was measured. Scatchard analysis of saturation binding curves was performed with Prism 4 GraphPad 
software (GraphPad software, San Diego, CA) using nonlinear regression analysis. The symbol ,  and  represent total binding 
(TB), non-saturable binding (NSB), and saturable binding (SB), respectively. E. Ramos cells (target) were labeled with bis(acetoxymethyl) 
2,2′:6′,2″-terpyridine-6,6″-dicarboxylate (BADTA). Freshly isolated human peripheral blood mononuclear cells PBMCs (effector) were 
used for allotyping of the Ulocuplumab (BMS-936564). Human PBMCs were cultured with labeled Ramos cells at 1:50 ratio of target/
effector cell (T/E) ratios in the presence or absence of rituximab, Ulocuplumab, or isotype (BMS-936564) for 1 h at 37°C. Ramos cells 
alone served as spontaneous release (SR) and Ramos cells lysed with 1% Triton X-100 served as total release (TR). The lysis was measured 
by using europium (Eu)-based detection. BMS-936564, Rituximab and their respective isotypes with varied concentrations were tested 
using Ramos cell line. F. Cell-based CDC assay of Ulocuplumab (BMS-936564) /Rituximab and their respective isotypes as controls: lysis 
of Ramos cells in the presence of human complement was measured by using Alamar Blue release. G. The stable transfected Jurkat cell line 
expressing FcgRIIIa and NFAT-RE luc was used as effector E. in an ADCC Reporter Bioassay from Promega. CLL cells (target, T) were 
plated in ratio of 1:1 with the effector cells. The effector: target cells were incubated in the presence or absence of rituximab or Ulocuplumab 
(BMS-936564), or obinutuzumab between 0.001-30 ug/ml of concentrations for 6 hrs at 37°C. Rituximab and obinutuzumab were used as 
positive controls. The reaction was developed by incubating the cells with Bio-GloTM reagent for 30 minutes at room temperature in dark. 
The plates were read on luminometer and following the background subtraction, relative-light units (RLU) were calculated for different 
antibodies/isotypes using GraphPad Prism software. H. Complement dependent cytotoxicity (CDC) for 10 μg/ml of either Ulocuplumab 
(BMS-936564), rituximab, obinutuzumab or isotype was tested in CLL cells after incubation with either 5% fresh human or heat inactivated 
serum (to denature complement) was measured by using CD19/CD5/Annexin V staining followed by flow cytomerty analysis. Rituximab 
and obinutuzumab were used as positive controls. The data are the mean and SD of triplicate cultures. The statistical data was analyzed 
using Bonferroni correction test in GraphPad Prism software.
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The pro-apoptotic activity of Ulocuplumab (BMS-
936564) was stronger on different cell lines and CLL 
cells compared to other commercially available CXCR4 
antibodies – 1D9,[18, 19] and 12G5 [20, 21]. In the case 
of 1D9 the IC50 was not achievable and for 12G5 was 32.1 
nM in CLL cells (Supplementary Figure 4). Additionally, 
in screening of different leukemia/lymphoma cell lines, we 
found that Ulocuplumab (BMS-936564), as compared to 
12G5 and 1D9 antibodies was, more effectively inducing 
in vitro cytotoxicity (Table 2). 
Ulocuplumab (BMS-936564) preferentially 
induces apoptosis in CLL/cancer cell lines, but not 
in normal lymphocytes
Leukemia cells from CLL patients with CLL-HR 
or CLL-LR disease were incubated with Ulocuplumab 
(BMS-936564) and apoptosis was evaluated after 48 hrs 
of culture. Despite of the presence of high-risk prognostic 
factors [unmutated IgVH genes, high levels of ZAP-70 
or TP53mut /Del(17p)], which are typically associated 
with poor clinical outcome and disease progression, we 
observed similar levels of apoptosis in CLL-HR and 
CLL-LR samples (Figure 4A). Interestingly, samples 
from patients with TP53mut /Del(17p) were sensitive to 
Ulocuplumab (BMS-936564), and showed comparable 
levels of apoptosis with CLL-HR and CLL-LR samples 
and the apoptosis levels were significantly higher than 
those observed after treatment with F-ara-A. 
The IC50 for different CLL subgroups including low-
risk, high-risk and TP53mut /Del(17p) were 4.9 nM, 9.8 
nM, and 11.6 nM, respectively. In contrast, the IC50 was 
not achieved in normal B and T lymphocytes. On the other 
hand, normal B and T lymphocytes appear to be resistant 
to the cytotoxic activity of Ulocuplumab (BMS-936564) 
with apoptosis levels that were significantly lower than 
those observed in CLL samples. (Figure 4A). 
Ulocuplumab (BMS-936564) induced apoptosis is 
independent of p53 status
To show that the activity of Ulocuplumab (BMS-
936564) was p53 independent, we incubated leukemia 
cells derived from either TP53wt or TP53mut /Del(17p) 
CLL patients and Ramos (TP53mut), and compared 
the level of apoptosis induced by F-ara-A, which is 
known to be a p53 dependent chemotherapy agent. [22] 
Ulocuplumab (BMS-936564) induced cell death in CLL 
TP53wt, TP53mut /Del(17p) and Ramos (TP53mut) with 
similar IC50 (2.7 nM, 2.7 nM, and 3 nM respectively). 
As expected, F-ara-A was active only in CLL TP53wt 
and the IC50 for F-ara-A in TP53mut /Del(17p) and 
Ramos (TP53mut) was not achieved even after using this 
compound at supra-physiological concentration (Figure 
4B).
Figure 3: % SIA induction by Ulocuplumab (BMS-936564) is CXCR4 specific as observed in Ramos and primary 
CLL cells but not in K562. A. Ramos and K562 cell lines were treated with different concentrations of Ulocuplumab (BMS-936564) 
and AMD3100 for 48 hrs followed by running the samples on flow cytometer to study the % SIA. Treatment with AMD3100 in Ramos/
K562/CLL did not induce significant % SIA as compared to Ulocuplumab (BMS-936564). In contrast, Ulocuplumab (BMS-936564) 
induced significant % SIA in Ramos and CLL cells (CXCR4+), but not in K562 (CXCR4-) as evaluated by flow cytometry). B. The CLL 
cells cultured either alone or with stromal cell support were treated with Ulocuplumab (BMS-936564) or AMD3100 for 48 hrs at 37oC 
followed by flow cytometer for measurement of % SIA. AMD3100 does not induce significant % SIA in CLL as compared to Ulocuplumab 
(BMS-936564). Ulocuplumab (BMS-936564) induced significant amount of % SIA in CLL cells alone or CLL co-cultured with stromal 
cell support.
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Ulocuplumab (BMS-936564) inhibits F-actin 
polymerization and cell migration
The functional activity of Ulocuplumab (BMS-
936564) was studied in CLL samples that underwent 
CXCR4 activation mediated by CXCL12. Using this 
model, CLL cells treated with CXCL12 underwent 
cytoskeletal reorganization measured by F-actin 
polymerization assay and chemotactic changes that were 
measured using a transwell migration assay. 
CXCL12 induced an average increase in actin 
polymerization of 152.54% after stimulation with 90 nM 
CXCL12 for 15 seconds at 37°C. Ulocuplumab (BMS- 
936564) at 200 nM (p < 0.0001) and 2 μM (p < 0.0001) 
concentrations significantly inhibited actin polymerization 
and reduced the peak response to CXCL12 by an average 
of 20-40%. Similarly, significant levels (p <0.0001) of 
inhibition were observed with AMD3100 at 4 μM and 
40 μM concentrations), which was used as control for 
CXCR4 inhibition (Figure 5A). 
CXCL12 induced chemotaxis and transwell 
migration in CLL cells with an average increase > 90% 
over base line (Figure 5B). Ulocuplumab (BMS-936564) 
(20 nM-2 μM) significantly inhibited cell migration by 
40- 58%. AMD3100 (40 μM) also inhibited significantly 
(p <0.05) the migration compared to the peak stimulation 
after CXCL12 (Figure 5B).
Ulocuplumab (BMS-936564) induction of 
programmed cell death (PCD) is caspase 
independent 
To study the mechanism(s) of Ulocuplumab 
(BMS-936564) induced apoptosis, we evaluated caspase 
activation in CLL cells as well as in normal B cells after 
incubation with this antibody. Ulocuplumab (BMS-
936564) induced significant caspase activation (caspase 2, 
3, 8, 9) in CLL cells but not in normal B cells (Figure 6A). 
However, inhibition of caspase activation with Z-VAD did 
not block Ulocuplumab (BMS-936564) induced apoptosis 
suggesting that caspase activation is not required for the 
pro-apoptotic activity of this antibody (Figure 6B).
Ulocuplumab (BMS-936564) induces cell death 
via production of reactive oxygen species (ROS) 
in CLL cells
Because the mechanism of action related to the pro-
apoptotic activity of Ulocuplumab (BMS-936564) appears 
to be caspase independent, we performed experiments to 
address other possible explanations including induction of 
reactive oxygen species (ROS), which has been associated 
with monoclonal antibody induction of cell death [23]. 
CLL cells were incubated with Ulocuplumab (BMS-
Figure 4: Ulocuplumab (BMS-936564) antibody induces apoptosis in CLL cells independent of TP53 status. A. The 
primary leukemia B-cells were obtained from CLL patients with or without TP53 mutation or Del(17p) [TP53mut /Del(17p)]. Normal B 
and T lymphocytes were obtained from healthy donors. The % SIA was measured in normal B, T cells, CLL cells, TP53mut /Del(17p) CLL 
cells, alone or co-cultured with stroma-NK-tert cells after treatment with 200 nM of Ulocuplumab (BMS-936564) for 48 hrs of incubation 
at 37°C. % SIA of Normal B and T cells was significantly less when compared to CLL-LR, CLL-HR and TP53mut /Del(17p) patients, 
showing that Ulocuplumab (BMS-936564) has a good therapeutic index. Ulocuplumab (BMS-936564) induced apoptosis in CLL cells 
regardless of TP53mut /Del(17p) mutation status, while normal B or T cells showed statistically-lower level of apoptosis. The data shows 
the results of samples analyzed in duplicate with the mean and its respective standard deviations. B. Representative CLL samples from each 
subgroup - TP53wt or TP53mut /Del(17p) and Ramos TP53 mutant were incubated for 48 hrs with the Ulocuplumab (BMS-936564) and 
Fludarabine (F-ara-A). Apoptosis was measured by flow cytometry.
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936564) or with controls (H2O2, Obinituzumab, F-ara-A, 
and Rituximab), and then were evaluated for superoxide 
production by using hydroxyethidium (HE) in conjunction 
with Annexin V to measure apoptosis. We observed that 
after 4 hrs of incubation, cells treated with Ulocuplumab 
(BMS-936564) showed a rapid increase in cell death 
and ROS production with levels that were significantly 
higher compared to untreated controls (p < 0.05). 
Positive controls for this experiment including H2O2 and 
Obinituzumab, an anti CD20 antibody known to induce 
ROS+ mediated apoptosis, showed an expected increase 
in ROS levels compared with untreated samples while 
isotype antibody control, rituximab and F-ara-A did not 
show an increase in ROS+/Annexin-V+ cells (Figure 7A). 
More over, ROS induction was a critical step required for 
Ulocuplumab (BMS-936564) to induce apoptosis. This 
was demonstrated when Tiron, a ROS inhibitor that has 
been extensively used in the previous studies [23-25], 
completely abrogated the ROS production and apoptosis 
induced by Ulocuplumab (BMS-936564) in leukemia cells 
(Figure 7B and 7C).
DISCUSSIONS
Chemokines and chemokine receptors are 
important for the migration of immune cells to the site 
of inflammation and play an important role maintaining 
the homeostasis in the tumor microenvironment [26, 27]. 
Particularly, CXCR4 expression in CLL regulates cell 
migration, homing to lymphoid tissues and could favor the 
formation of minimal residual disease after treatment by 
inducing a “protective” anti-apoptotic microenvironment 
[28]. Therefore, the cellular signaling mediated by CXCR4 
constitutes a potential biological target in CLL and other 
malignancies. 
Ulocuplumab (BMS-936564) is a first in class, 
fully human IgG4 monoclonal antibody that has been 
engineered to specifically bind to CXCR4 [17]. In vitro 
studies have shown that Ulocuplumab (BMS-936564) 
has a potent anti-tumor activity in established tumors 
including AML, NHL, and multiple myeloma xenograft 
models [17]. In addition, preliminary reports from 
clinical studies in hematological malignancies using this 
antibody have shown encouraging clinical activity [29]. 
However, because the precise mechanism(s) of action of 
this antibody is not completely understood, we focused 
our studies to provide additional insights regarding this 
particular question. 
We found that primary leukemia cells from CLL 
patients have significantly higher levels of CXCR4 
Figure 5: Inhibition of CXCL12-induced response and migration of primary CLL cells in a transwell assay by 
Ulocuplumab (BMS-936564) and AMD3100. A. Intracellular F-Actin was measured using FITC-labeled phalloidin in CD19/CD5- 
pre-labeled CLL cells after stimulation with CXCL12 (90 nM) for 15 seconds. CLL cells from 10 patients (5 HR & 5 LR) were treated with 
no compounds (control), AMD3100 (4-40 μM) or Ulocuplumab (BMS-936564) (20-2000  nM) prior to stimulation and the representative 
example of F-actin polymerization is shown. All samples are plotted relative to the mean fluorescence of the sample without any addition 
of the chemokine CXCL12. B. A total of 5x105 cells per well were plated overnight before the experiment. The cells were incubated with 
Ulocuplumab (BMS-936564) and AMD3100 (using indicated concentrations) for one hour and loaded on to the transwell chamber and 
incubated for two hrs in the presence of CXCL12 (12.5 nM) or media control. After that, cells that migrated to the lower chamber were 
counted using flow cytometry.
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expression compared with normal B cells and that high-
risk prognostic factors do not influence the level of 
expression of this chemokine receptor. None of the patients 
were treated in the phase-I clinical trial for Ulocuplumab 
(BMS-936564). This is in agreement with previous reports 
from our group and others [30-32]. More over, CLL cells 
did not show expression of CXCL12 (CXCR4 ligand) by 
flow cytometry and CXCL12 gene expression by RT-PCR 
was also negative in the large majority of samples. This 
suggests that activation of CXCR4 induced by CXCL12 
occurs either by cell-cell interactions with non-leukemia 
CXCL12 expressing cells, likely located in lymphatic 
tissues, or mediated by soluble CXCL12. 
Ulocuplumab (BMS-936564) showed a nanomolar 
binding affinity to CXCR4 expressed in Ramos cells 
with a CXCR4 receptor concentration that was 3-4 times 
higher than peripheral blood mononuclear cells (150,000 
vs. 61,000-receptor density / cell). The pro-apoptotic 
activity of Ulocuplumab (BMS-936564) was dependent 
on membrane expression of CXCR4, and as expected for 
an IgG4 antibody, this molecule did not induce ADCC or 
CDC effector functions in Ramos or CLL cells. 
Ulocuplumab (BMS-936564) induced CLL death 
regardless of the presence of prognostic factors that 
we used to segregate CLL-HR and CLL-LR [ZAP-
70 expression, IgVH gene mutation status, TP53mut /
Figure 6: Effect of Ulocuplumab (BMS-936564)-mediated apoptosis in CLL cells is caspase-independent. A. Cells were 
treated for 6 hrs with either 200 nM of Ulocuplumab (BMS-936564) or isotype control (IC). 100 µg of protein was taken from each 
treatment for caspase analysis. Caspase 2, 3, 8 and 9 were activated upon treatment with the Ulocuplumab (BMS-936564) antibody. There 
was a significant difference between normal versus CLL cells for caspase 2, 3, 8, and 9. Caspase activity of cells incubated in media only 
was used as a baseline control. Each value is expressed as mean ± S.D. of two independent experiments. B. CLL cells were incubated with 
Ulocuplumab (BMS-936564) (200 nM), F-ara-A (10 μM), and Etoposide (30 μM) for 48 hrs either alone or in combination with different 
concentrations of a pan-caspase inhibitor, Z-VAD-FMK (10, 30, 90 μM). CLL cells viability was analyzed by CD19+/CD5+/Annexin-V 
staining followed by flow cytometry. Statistical significance was determined by using Dunnett’s multiple comparison test (* p < 0.05; ** 
p<0.01, *** p < 0.001). Z-VAD inhibited apoptosis in a dose dependent manner when apoptosis was induced by chemotherapy controls but 
not by Ulocuplumab (BMS-936564) (untreated media control vs. 0-90 μM Z-VAD , p < 0.0001).
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Del(17p)] patients. However, in this cohorts of patients 
analyzed, we noticed that patients with TP53mut /Del(17p) 
have a lower response compared to other CLL samples. 
Despite of that, cell death induced by Ulocuplumab 
(BMS-936564) in this group of high-risk patients was 
significantly better than the low response observed with 
F-ara-A (p < 0.0001). These results suggest that the 
mechanism of cell death associated with Ulocuplumab 
(BMS-936564) is, at least in part, p53 independent, 
a finding that have significant clinical implications 
particularly in the treatment of refractory cancer where 
the majority of cases are associated with p53 dysfunction 
[33]. Among other anti-CXCR4 antibodies tested, 12G5 
and 1D9, only 12G5 was able to induce cell death in CLL 
alone or co-cultured with stroma-NK-tert cells support, 
but the effect was weaker as compared to Ulocuplumab 
(BMS-936564). The reason for poor cytotoxicity of 1D9 
may be because unlike 12G5, it does not compete for 
CXCL12 binding to CXCR4 [19, 34, 35]. 
Ulocuplumab (BMS-936564) binds to CXCR4 
Figure 7: Reactive oxygen species (ROS) mediated mechanism of cell death by BMS-936564 in patients’ derived CLL 
cells. A. Primary CLL cells derived from patients were treated for 4 hrs either with 0.1% H2O2, 10 ug/ml of obinutuzumab, Rituximab, 
Ulocuplumab (BMS-936564) antibody or F-ara-A at the indicated concentrations. ROS production and cell death were assessed by flow 
cytometry. ROS+/Annexin-V+ double positive cells indicate the population of cell undergoing cell death with concurrent release of ROS 
(Upper right quadrant). Cells incubated in media only serve as base line control. This experiment represents typical data from three separate 
experiments conducted with duplicates per each incubation condition. B. The cells were incubated alone with Tiron (30 mM) or 10 μg/ml 
of either rituximab, obinutuzumab, Ulocuplumab (BMS-936564), 0.1% of  H2O2 and 10 μM Fludarabine (F-ara-A) with 30 mM of Tiron 
for 4 hrs at 37oC . To measure ROS production, following CD19/CD5 labeling, cells were labeled with hydroxyethidium dye and incubated 
for 20 minutes at room temperature followed by flow cytometry analysis. The data presented represent mean ROS production± S.D. C. The 
cells were incubated alone with Tiron (30 mM) or 10 μg/ml of either rituximab, obinutuzumab, Ulocuplumab (BMS-936564), 0.1% of H2O2 
and 10 μM Fludarabine (F-ara-A) with 30 mM of Tiron for 4 hrs at 37oC . TheThe percentage (%) cell death was measured using CD19/
CD5/Annexin-V labeling followed by flow cytometry analysis. The representative data for ROS and % cell death has been shown from the 
same patient. The data presented represent mean ROS production± S.D.
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and blocks CXCL12 induced cytoskeletal changes and 
migration similarly to AMD3100. However, the lack 
of direct anti-cancer activity shown by AMD3100 and 
other synthetic peptide CXCR4 inhibitors, [6, 31, 36] 
suggest that binding to CXCR4 and inhibition of CXCR4-
CXCL12 signaling is not sufficient to trigger cell death. 
This is further supported by evidence that Ulocuplumab 
(BMS-936564) induced similar levels of cell death in CLL 
cells cultured alone (lacking CXCL12 stimulation) or co-
cultured with CXCL12 expressing stromal cell support. 
We observed that Ulocuplumab (BMS-936564) 
induces pancaspase activation (caspases 2, 3, 8, 9) but this 
is not sufficient to induce cell death. This is supported by 
the fact that the potent caspase inhibitor Z-VAD did not 
block cell death induced by this antibody as it did with 
chemotherapy treated controls (etoposide and F-ara-A). 
Caspase-independent cell death has been recognized 
as an alternative pathway that involves proteins released as 
a result of mitochondrial outer membrane permeabilization 
(MOMP) [37, 38]. These proteins including AIF, 
HtrA2/Omi, and endonuclease G, can undergo nuclear 
translocation to induce an early chromatic condensation, 
ROS production, DNA damage, lysosome activation and 
proteolysis mediated by release of cathepsin and proteases. 
Because our data suggested the presence of 
this caspase-independent mechanism, we performed 
experiments to analyze the role of ROS in Ulocuplumab 
(BMS-936564) mediated cell death. We found that upon 
incubation with Ulocuplumab (BMS-936564), CLL cells 
generated ROS that were detected using dihydroethidium 
(HE) staining. HE is a cell-permeable fluorogenic probe 
that reacts with ROS to form ethidium, which intercalates 
within double-stranded DNA in the nucleus and emits red 
fluorescence. Cells that release ROS also underwent cell 
membrane changes associated with apoptosis including 
phosphatidylserine (PS) translocation from the inner to the 
outer leaflet of the cellular membrane that was detected by 
fluorescent staining with annexin V. The pattern of ROS 
production and apoptosis induced by Ulocuplumab (BMS-
936564) was similar to obitunutuzumab (Gazyva), another 
antibody that has been recently shown to induce ROS 
dependent cell death. More over, Tiron, a well-known 
peroxide inhibitor/scavenger, was capable of rescuing 
cells from Ulocuplumab (BMS-936564) induced cell 
death confirming that ROS production is essential for this 
antibody induction of apoptosis. 
Overall, we show here that Ulocuplumab (BMS-
936564), a specific anti-CXCR4 antibody, binds to 
CXCR4 with low affinity and blocks CXCL12 mediated 
activation-chemotaxis. This antibody induces apoptosis 
in CLL cells regardless of the presence of high-risk 
prognostic factors in a p53 independent manner. In 
addition, Ulocuplumab (BMS-936564) induces cell death 
by a caspase-independent mechanism that involves ROS 
release. These data highlight the relevance of the CXCR4-
CXCL12 pathway as a target in cancer therapy and 
provide additional rationale for ongoing clinical studies 
using Ulocuplumab (BMS-936564) in hematological 
malignancies including CLL.
MATERIALS AND METHODS
Collection and isolation of PBMCs from CLL 
patients
Peripheral3 blood mononuclear cells (PBMC) from 
CLL patients were obtained from the CLL Research 
Consortium (CRC) tissue repository, Moores Cancer 
center, University of California, San Diego (UCSD), La 
Jolla. After CLL diagnosis was confirmed, [39] patients 
provided written informed consent for blood sample 
collection on a protocol approved by the Institutional 
Review Board of the Moores UCSD Cancer Center, in 
accordance with the Declaration of Helsinki [40]. 
The details of the cell culture for primary CLL 
and different cell lines (Table 1), flow cytometry based 
CXCR4, CXCL12 profiling, cell death, apoptosis 
measurement, CXCR4 binding, F-actin polymerization, 
migration, and ROS detention and inhibition, Z-VAD 
assay for caspase activation, [41] and dependency assays 
are provided in the, “Supplementary Materials and 
Methods”[42-44]. Leukemia samples from patients with 
CLL were divided in two subgroups i.e. high risk (CLL-
HR) and low risk (CLL-LR), based on the presence of 
high-risk prognostic makers including ZAP-70, CD38, and 
IGHV mutational status. 
Calculation of specific induced apoptosis (SIA)
In order to discriminate the compound specific 
induced apoptosis vs. background spontaneous cell 
death from in vitro culture conditions, we calculated the 
percentage of specific induced apoptosis (% SIA) using 
the following formula: % SIA = [(compound induced 
apoptosis – media only spontaneous apoptosis) / (100- 
media only spontaneous apoptosis)] × 100.
Statistical analysis
The data sets were analyzed using GraphPad 
Prism software (v. 5.0c; San Diego, CA). The Statistical 
significance was determined by using paired or 
unpaired Student’s t test or one-way ANOVA followed 
by Bonferroni correction’s multiple comparisons test. 
Statistical differences for the mean values are indicated 
as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001; and 
****, p < 0.0001. The IC50 value was defined as the drug 
concentration that inhibits 50% cell growth compared with 
untreated controls and calculated by Graphpad Prism 6.0 
software. Unless indicated, data are presented as the mean 
± SEM. 
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